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ABSTRACT
The aim of the study was to investigate the acute effect of GH per
se, independent from its lipolytic activity, on glucose and lipid oxi-
dation and glucose turnover in seven healthy subjects. Five tests
lasting 360 min were performed. Each test consisted of a 4-h equil-
ibration period followed by a euglycemic hyperinsulinemic (25 mU/
kgzh) clamp lasting 2 h. In test 1 (control experiment) saline was
infused, leaving GH and FFA at basal levels. In tests 2, 3, and 4, GH
was infused (80 ng/kgzmin) to increase GH levels. Whereas in test 2
FFA levels were free to increase due to GH lipolytic activity, in test
3 FFA elevation was prevented by using an antilipolytic compound
(Acipimox) that allowed evaluation of the effect of GH at low FFA
levels. In test 4 (GH1Acipimox1heparin) GH infusion was associated
with the administration of Acipimox and heparin to maintain FFA at
the basal level to evaluate the effect of GH per se independent from
GH lipolytic activity. In test 5 Acipimox and a variable heparin in-
fusion were given to evaluate possible effects of Acipimox other than
the inhibition of lipolysis.
During the euglycemic hyperinsulinemic clamp in the presence of
high GH and FFA levels (test 2), glucose oxidation was significantly
lower and lipid oxidation was significantly higher than in tests 1, 3,
4, and 5. During the same period, hepatic glucose production was
completely suppressed in the control study (test 1; 94%) and in test
5 (99.6%), whereas it was significantly less inhibited (65%, 74%, and
73%) when GH was administered in tests 2, 3, and 4.
In conclusion, these results suggest that GH directly mediates the
reduction of insulin’s effect on the liver. In addition, the effect of GH
on glucose and lipid oxidation is not direct, but is mediated by its
lipolytic activity. (J Clin Endocrinol Metab 84: 1658–1663, 1999)
MANY STUDIES have shown that GH can induce in-sulin resistance (1–3), although the mechanism by
which an acute increase in its levels can decrease glucose
uptake is still debated. In vitro studies have shown that GH
decreases glucose uptake without affecting glucose oxida-
tion in human erythrocytes (4, 5), fat tissue (6), or diaphragm
cultures (7). In vivo, hepatic glucose seems to reduce forearm
glucose uptake, glucose oxidation, and glycogen synthase
activity and to impair insulin suppression of hepatic glucose
production (8–10) in favor of increased lipid oxidation. Re-
cently, Neely et al. (11) have shown that after an overnight
GH infusion in normal subjects, both GH and free fatty acid
(FFA) levels were positively correlated with the increase in
peripheral and hepatic insulin resistance. In addition, in most
of the previous studies, high levels of GH were invariably
associated with high circulating levels of glycerol, FFA, and
b-hydroxybutyrate (8–10, 12, 13). Therefore, it remains un-
clear whether the effect of GH on glucose metabolism is
direct (10) or mediated by GH-induced lipolytic action
through the well known glucose-fatty acid cycle or Randle
cycle, as hypothesized by Davidson et al. (14). Indeed, an
increase in FFA levels can compete with glucose utilization
on the oxidative pathway in muscle and induce insulin re-
sistance (15–18).
The purpose of this study was to investigate the acute
effect of a systemic elevation of GH levels independent from
its lipolytic action on glucose and lipid oxidation and hepatic
glucose production (HGP) in normal man. Our results indi-
cate that GH directly decreases the insulin suppressibility of
HGP. By contrast, GH influences glucose and lipid oxidation
only when its ability to stimulate lipolysis is maintained.
Subjects and Methods
The experimental protocol was approved by the local ethical com-
mittee, and informed consent was obtained from each volunteer. Seven
healthy male subjects (mean age, 25 6 3 yr; weight, 72.4 6 4 kg; fat-free
mass, 55.9 6 2.8 kg) underwent three different tests (lasting 360 min) in
random order, with at least a 15-day interval between two consecutive
tests. In each test a 4-h equilibration period (0–240 min) was followed
by a euglycemic hyperinsulinemic (25 mU/kgzh) clamp lasting 2 h
(240–360 min), with blood glucose maintained at basal values by means
of a variable glucose (20%) infusion (19).
Test 1 was the control experiment. During this test saline was infused,
leaving GH and FFA at their basal levels.
Test 2 was designed to study the effect of increased GH and FFA
levels. GH was infused (80 ng/kgzmin) to achieve circulating GH levels
similar to those seen in major surgery (20, 21) and severe trauma (22).
A concomitant elevation of FFA levels was induced by the lipolytic effect
of GH.
Test 3 allowed evaluation of the effect of GH in the presence of low
FFA levels. GH was infused as in test 1, whereas lipolysis was inhibited
using Acipimox (250 mg at 0 and 120 min). Acipimox is a nicotinic acid
analog that blocks the spontaneous as well as noradrenaline-, theophy-
line-, and GH -induced lipolysis from the adipose tissue.
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In the same subjects two additional tests (tests 4 and 5) were carried
out. Test 4 was performed to evaluate the effect of GH per se independent
from the effect of FFA. GH was infused as in test 2, and FFA were kept
at the basal levels observed in test 1 despite the administration of Acipi-
mox (250 mg at 0 and 120 min) by giving a variable heparin infusion.
Test 5 was performed to evaluate whether Acipimox could show
metabolic effects other than inhibition of lipolysis. Also in this case, FFA
were kept at the basal levels as in test 1 despite the administration of
Acipimox (250 mg at 0 and 120 min) by giving a variable heparin
infusion.
In tests 4 and 5 heparin infusion was modified according to the
plasma measurement of FFA levels performed using COBAS FARA
every 20 min. To achieve this goal, the following changes were per-
formed in the enzymatic colorimetric method usually used for FFA
assay. First, it was automated on a centrifugal analyzer (COBAS FARA
II). The total time of the procedure was reduced to 8 min, allowing us
to perform measurements of FFA every 20 min during both tests. The
present method correlated with a standard manual procedure (r 5 0.93;
slope 5 0.85; intercept 5 0.14 mmol/L; P , 0.0001). Intra- and interassay
coefficients of variation were 3.01% and 4.24%, respectively.
On the morning of each test, a 20-gauge plastic cannula (Abbocath T,
Abbocath, Ireland Ltd., Sling, Ireland) was inserted in a dorsal vein of
one hand in a retrograde position, and the hand was maintained at 55
C for intermittent sampling of arterialized blood (glucose, FFA, insulin,
GH, and glucagon). A 20-gauge plastic cannula was inserted into a large
antecubital vein of the same arm for the administration of different
infusions. The total glucose disposal rate was evaluated isotopically by
means of a prime (5 mg/kg) continuous (0.05 mg/kgzmin) infusion of
[6,6-2H2]glucose. During the clamp period, blood glucose was kept con-
stant by means of a variable infusion of 20% dextrose. A fixed amount
of dideuterated glucose was also added to the glucose bag (;1.4% cold
glucose) to maintain isotopic enrichment constant (23). Both the rate of
appearance (Ra) and the rate of disappearance (Rd) of unlabeled glucose
were calculated with Steele’s model (24), taking into account the non-
negligible stable isotope mass as indicated previously (25). HGP was
derived by subtracting the known constant glucose infusion rate from
the Ra.
For 30 min immediately before and during the last 30 min of the
euglycemic clamp, the rates of glucose and lipid oxidation were calcu-
lated at 1-min intervals using indirect calorimetry. Oxygen uptake and
carbon dioxide production were calculated as previously described (26).
Protein oxidation was calculated multiplying urinary N excretion by
6.25 (26) and was normalized by urea clearance (27). The urinary ni-
trogen excretion rate was calculated by collecting urine throughout the
test.
Assays
Changes in glucose infusion rates were made according to measure-
ments obtained every 5 min using a glucose analyzer (YSI, Inc., Yellow
Springs, OH). All samples were assayed for insulin, GH, and glucagon
in a single assay. The methods to measure hormones and isotopic en-
richment of [6,6-2H2]glucose have been reported previously (28, 29).
Statistical analysis
All values are expressed as the mean 6 se at each time interval.
Multiple comparisons among tests were performed by Scheffe’s F test
when appropriate.
Results
Metabolic and hormone levels
Figure 1 shows the insulin, glucose, GH, and FFA profiles
observed during the five studies. For the sake of clarity, we
will discuss the preclamp and clamp periods separately.
Preclamp period (0–240 min). Glucose and insulin levels were
similar at the baseline in the five tests (Fig. 1).
GH levels remained at basal levels during the control
study (test 1). GH levels increased to a similar extent (range,
55–70 ng/mL) during tests 2, 3, and 4. During the infusion
of GH alone (test 2), FFA increased significantly, achieving
levels significantly higher than those observed in the other
four tests. In contrast, during test 3, FFA levels were sup-
pressed (P , 0.05 vs. tests 1, 2, 4, and 5). During tests 4 and
5, FFA levels were successfully clamped at the basal levels
observed in the control study (Fig. 1).
Insulin-like growth factor I levels before the start of the
FIG. 1. Blood glucose, serum insulin, serum GH, and plasma FFA
profiles (mean 6 SE) during the different tests. Test 1 was the control
experiment; saline was infused, leaving GH and FFA at their basal
levels. Test 2 was designed to study the effects of increased GH and
FFA levels; GH was infused alone. Test 3 allowed evaluation of the
effect of GH in the presence of low FFA levels; GH was infused as in
test 2, and Acipimox was administered orally to inhibit lipolysis. Test
4 was carried out to evaluate the effect of GH per se independent from
the effect of FFA; GH was infused as in test 2, and FFA was kept at
the basal level by the administration of Acipimox and variable hep-
arin infusion. Test 5 was performed to evaluate whether Acipimox
could have metabolic effects other than inhibition of lypolysis; FFA
were kept at basal levels by the administration of Acipimox and
variable heparin infusion. *, P , 0.05, test 2 vs. tests 1, 3, 4, and 5;
§, P , 0.05, test 3 vs. tests 1, 4, and 5.
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study were similar in all tests (test 1, 195.3 6 17.7; test 2,
185.8 6 20.9; test 3, 230.3 6 20.3; test 4, 203.5 6 21.6; test 5,
210.8 6 12.8 ng/mL). Glucagon levels remained unchanged
in all tests (Table 1).
Clamp period (240–360 min). Glucose levels were successfully
clamped in all tests, with a coefficient of variation of less than
5% (Fig. 1). Insulin levels reached a plateau between 210–260
pmol/L (Fig. 1). GH levels remained at the plateau values
achieved before the clamp period in all tests (Fig. 1). FFA
decreased in all tests, remaining higher in test 2 with respect
to the other four tests. No significant differences were found
for FFA among tests 1, 3, 4, and 5. Insulin-like growth factor
I levels remained unchanged during the study in all tests (test
1, 202.1 6 17.9; test 2, 189.9 6 15.1; test 3, 215.1 6 22.6; test
4, 193.8 6 17.3; test 5, 200.7 6 15.9 ng/mL).
No significant differences were found in glucagon levels
at the end of the study in all tests (Table 1).
Glucose metabolism and indirect calorimetry results
In Table 2 are reported the glucose (atom percent excess;
APE) enrichment during the last 30 min of the preclamp and
clamp periods.
Table 3 reports the glucose turnover results, i.e. Rd and
HGP. Figure 2 shows the glucose and lipid oxidation results.
Again, for the sake of clarity we will discuss the preclamp
and clamp periods separately.
Preclamp period (0–240 min). Rd and HGP were not signifi-
cantly different among the tests, although Rd and HGP
tended to be higher during tests 2, 3, and 4 (i.e. when GH was
infused) than during tests 1 and 5. When pooling the data
from the five studies, a positive significant correlation be-
tween GH levels and HGP was found (r 5 0.49; P , 0.01; data
not shown). Glucose oxidation was significantly lower dur-
ing test 2 than during the other four tests (Fig. 2). Lipid
oxidation was significantly higher during test 2 than during
tests 3 and 4 (P , 0.05; Fig. 2). In addition, lipid oxidation was
significantly lower during test 3 than during tests 1 and 5
(P , 0.05). The protein oxidation rate was similar during all
tests (data not shown).
Clamp period (240–360 min). At the end of the clamp period,
the glucose infusion rate (M value) was significantly lower
during test 2 than during the other four tests (Table 3). Rd
was not significantly different among the tests, whereas HGP
was significantly lower in tests 1 and 5 than in the other tests.
If the HGP results are expressed in terms of percent inhibi-
tion with respect to values during the preclamp period, HGP
inhibition was 94% in test 1 and 99.6% in test 5 compared to
65%, 74%, and 73% in tests 2, 3, and 4, respectively (P , 0.05,
tests 1 and 5 vs. tests 2–4; Table 3). Once again, GH levels
remained significantly correlated with HGP (r 5 0.53; P ,
0.01; data not shown).
Glucose oxidation increased significantly in all tests, but
remained significantly lower during test 2 than during the
other tests (Fig. 2). Lipid oxidation remained significantly
higher during test 2 than during the other tests. Protein
oxidation was similar during all tests (data not shown).
Discussion
The results of the present study demonstrate the existence
of a direct effect of GH on HGP independent of a simulta-
neous increase in FFA levels. This result was obtained with
the measurement of total body glucose metabolism using an
isotope tracer methodology. The possibility of determining
total body glucose disposal (Rd) and the amount of the glu-
cose infusion rate (M value) during the clamp allowed us to
correctly measure the HGP during the clamp period. During
both preclamp and clamp periods, Rd was not different
among tests, although it tended to be decreased during the
clamp period in test 2. These data were due to the fact that
during the infusion of GH alone (test 2), the M value was
significantly decreased and HGP was significantly increased
compared to those during the control study (test 1).
In the period before the beginning of the glucose clamp,
although HGP during GH infusion (with or without Acipi-
mox) did not significantly increase with respect to the control
test with saline infusion, a significant positive correlation
between GH and HGP steady state levels was found. Such an
action of GH is consistent with the results of previous studies
showing hepatic receptors for GH (30–32) and with the pres-
ence of a direct inhibitory effect of GH on insulin binding in
the liver (30–32) but not in muscle (8). Previous studies have
been shown that after receptor binding, multiple signaling
events occur that are mediated by the GH, including the
tyrosine phosphorylation and activation of several cellular
proteins (33, 34). In cultured cells, GH determines an acti-
vation of JAK2 (Janus kinase-2) and several members of the
STAT (signal transducer and activator of transcription) fam-
ily of proteins, STAT1, -3, and -5 (35–37). The phosphorylated
STAT proteins translocate into the nucleus, bind to DNA, and
can activate the transcription of specific genes. The admin-
istration of GH in vivo to hypophysectomized rats induced a
stimulation of STAT1, -3, and -5 in liver nuclear fraction
(38–40), whereas this effect has been shown in nonhypophy-
TABLE 1. Glucagon levels (picograms per mL) at baseline and at the end of the preclamp and clamp periods
Test 1 Test 2 Test 3 Test 4 Test 5
Baseline 125.3 6 33.7 131.5 6 27.6 181.9 6 48.6 135.3 6 13.2 138.3 6 17.9
Preclamp period 149.8 6 61.0 125.5 6 23.2 141.4 6 29.2 140.0 6 7.8 143.0 6 16.5
Clamp period 109.0 6 29.3 107.9 6 17.5 121.3 6 33.5 134.2 6 5.8 140.0 6 15.1
Test 1 was the control experiment; saline was infused, leaving GH and FFA at their basal levels. Test 2 was designed to study the effects
of increased GH and FFA levels; GH was infused alone. Test 3 allowed evaluation of the effect of GH in the presence of low FFA levels; GH
was infused as in test 2, and Acipimox was administered orally to inhibit lipolysis. Test 4 was carried out to evaluate the effect of GH per se
independent from the effect of FFA; GH was infused as in test 2, and FFA was kept at the basal level by the administration of Acipimox and
variable heparin infusion. Test 5 was performed to evaluate whether Acipimox could have metabolic effects other than inhibition of lypolysis;
FFA was kept at the basal level by the administration of Acipimox and variable heparin infusion. Values are the mean 6 SE.
1660 PIATTI ET AL. JCE & M • 1999
Vol 84 • No 5
sectomized rats for JAK2 and STAT5 (41). Recently, the mea-
surement of tyrosine phosphorylation of insulin receptor
substrate-1 in liver and muscle of normal rats treated with
GH showed a 10% decreased of this expression in liver com-
pared to no effect in muscle (41).
At the end of the euglycemic hyperinsulinemic clamp, in
the presence of mild hyperinsulinemia, HGP was completely
suppressed only during tests 1 and 5, when GH was not
administered. When GH was infused, HGP was significantly
less inhibited compared to that in the control study. This
effect of GH on HGP was virtually the same when FFA were
suppressed by Acipimox or maintained at the basal levels by
using Acipimox and heparin. These data suggest that GH is
able to acutely mediate the reduction of hepatic sensitivity to
insulin independent of FFA levels. They also provide a pos-
sible interpretation of previous results in IDDM patients with
GH deficiency, in whom an infusion of heparin to increase
FFA levels did not increase HGP when performed during the
early hours of the morning (42).
Our results indicate that the decreases in the M value and
glucose oxidation after GH administration are mediated by
GH-increased FFA levels rather than by a direct effect of GH
per se. This can be appreciated by comparing the results
obtained during the preclamp period of the five tests per-
formed in the present study. In keeping with the findings of
Moller et al. (9), glucose oxidation was significantly de-
creased, and lipid oxidation was significantly enhanced dur-
ing an acute infusion of GH (test 2). However, when lipolysis
and lipid oxidation were completely blocked by Acipimox
(test 3) or were maintained at the basal levels by the admin-
istration of Acipimox and heparin (test 4), the effect of GH
on glucose oxidation were similar to that found during saline
infusion (test 1). Of note is that a similar pattern of results was
found at the end of the euglycemic clamp. These findings
suggest that the effect of GH on glucose and lipid oxidation
is not direct, but is mediated by its lipolytic activity. This
conclusion is supported by previous in vitro studies showing
that 4- to 6-h exposure to GH did not affect either glucose
oxidation by adipose tissue from hypoxic rats (43) or glucose
conversion to glycogen in soleus muscle in rats (44).
As in the present study Acipimox was used to inhibit
lipolysis, it could be argued that the effect on glucose me-
tabolism seen in this study not only was due to an acute
decrease in FFA levels but, to some extent, was also related
to the drug. Fulcher et al. (45) administered 1000 mg Acipi-
mox (twice the amount used in the present study) and si-
multaneously clamped FFA levels (at 0.4 mmol/L) by in-
tralipid infusion. They found that glucose oxidation during
an euglycemic hyperinsulinemic clamp was unaffected by
the drug, and the increase in glucose disposal was only due
TABLE 2. Glucose enrichment (APE) during the last 30 min of the preclamp and clamp periods
Test 1 Test 2 Test 3 Test 4 Test 5
Preclamp period
210 min 2.50 6 0.07 2.27 6 0.11 2.28 6 0.06 2.16 6 0.15 2.55 6 0.15
220 min 2.51 6 0.11 2.23 6 0.10 2.26 6 0.08 2.15 6 0.13 2.60 6 0.10
230 min 2.56 6 0.14 2.22 6 0.12 2.24 6 0.07 2.14 6 0.13 2.55 6 0.15
240 min 2.52 6 0.12 2.22 6 0.12 2.24 6 0.06 2.18 6 0.14 2.58 6 0.17
Clamp period
330 min 2.55 6 0.09 2.73 6 0.14 2.51 6 0.09 2.55 6 0.09 2.66 6 0.16
340 min 2.58 6 0.10 2.73 6 0.14 2.50 6 0.10 2.53 6 0.12 2.66 6 0.13
350 min 2.62 6 0.11 2.69 6 0.12 2.48 6 0.10 2.53 6 0.12 2.69 6 0.15
360 min 2.55 6 0.10 2.72 6 0.11 2.52 6 0.10 2.54 6 0.11 2.66 6 0.13
Test 1 was the control experiment; saline was infused, leaving GH and FFA at their basal levels. Test 2 was designed to study the effects
of increased GH and FFA levels; GH was infused alone. Test 3 allowed the evaluation of the effect of GH in the presence of low FFA levels;
GH was infused as in test 2, and Acipimox was administered orally to inhibit lypolysis. Test 4 was carried out to evaluate the effect of GH per
se independent from the effect of FFA; GH was infused as in test 2, and FFA was kept at the basal level by the administration of Acipimox
and variable heparin infusion. Test 5 was performed to evaluate whether Acipimox could have metabolic effects other than inhibition of lypolysis;
FFA was kept at the basal level by the administration of Acipimox and variable heparin infusion. Values are the mean 6 SE.
TABLE 3. Glucose turnover results during preclamp and clamp periods
Test 1 Test 2 Test 3 Test 4 Test 5
Preclamp period
Rd (mmol/kg FFM/min) 14.14 6 0.54 15.55 6 0.52 15.39 6 0.23 17.13 6 1.43 12.78 6 1.44
HGP (mmol/kg/min) 10.83 6 0.51 12.16 6 0.53 12.01 6 0.28 12.79 6 0.92 10.19 6 0.46
Clamp period
M value (mmol/kg FFM/min) 24.44 6 1.26 14.96 6 1.62a 23.25 6 2.89 19.94 6 1.51 24.89 6 3.24
Rd (mmol/kg FFM/min) 25.24 6 1.52 20.46 6 1.52 27.29 6 2.07 24.59 6 1.84 23.84 6 3.25
HGP (mmol/kg/min) 0.60 6 0.46b 4.32 6 0.57 3.11 6 0.83 3.45 6 0.57 0.02 6 0.25b
% Inhibition HGP 94.8 6 4.1b 65.1 6 3.9 73.7 6 7.2 73.3 6 3.3 99.6 6 2.4b
Test 1 was the control experiment; saline was infused, leaving GH and FFA at their basal levels. Test 2 was designed to study the effects
of increased GH and FFA levels; GH was infused alone. Test 3 allowed the evaluation of the effect of GH in the presence of low FFA levels;
GH was infused as in test 2, and Acipimox was administered orally to inhibit lipolysis. Test 4 was carried out to evaluate the effect of GH per
se independent from the effect of FFA; GH was infused as in test 2, and FFA was kept at the basal level by the administration of Acipimox
and variable heparin infusion. Test 5 was performed to evaluate whether Acipimox could have metabolic effects other than inhibition of lypolysis;
FFA was kept at the basal level by the administration of Acipimox and variable heparin infusion. Values are the mean 6 SE.
a P , 0.05 vs. tests 1, 3, 4, and 5.
b P , 0.05 vs. tests 2, 3, and 4.
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to the enhancement of nonoxidative glucose disposal. The
results of our study are in agreement with these findings, as
glucose oxidation was similar when Acipimox was admin-
istered (tests 3–5) and during saline infusion (test 1). Thus,
it is most likely that in our study Acipimox did not appre-
ciably influence glucose metabolism. These conclusions are
also supported by previous studies in which Acipimox was
unable to enhance either the insulin-mediated forearm glu-
cose uptake during euglycemic hyperinsulinemic clamp in
healthy subjects (46) or the suppression of HGP by insulin in
noninsulin-dependent diabetic subjects when it was admin-
istered in association with heparin to maintain high FFA
levels (47).
As chronic therapy with Acipimox seems to increase glu-
cagon levels (48), acute changes in this hormone after ad-
ministration of the drug could explain some of the differ-
ences in HGP among tests. However, in the present study the
measurement of glucagon levels at the end of the preclamp
and clamp periods did not show any statistical differences
among tests. This suggests that Acipimox does not acutely
influence glucagon levels in these particular conditions.
In conclusion, our results indicate that GH directly medi-
ates the reduction of insulin’s effect on the liver. In addition,
under acute GH administration, GH influences glucose and
lipid oxidation only when its ability to stimulate lipolysis is
maintained.
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